Last reviewed · How we verify
KN026 monotherapy
At a glance
| Generic name | KN026 monotherapy |
|---|---|
| Also known as | KN026 |
| Sponsor | Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer (PHASE1)
- Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KN026 monotherapy CI brief — competitive landscape report
- KN026 monotherapy updates RSS · CI watch RSS
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd portfolio CI